Lupiwighteone

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Model organisms1

Outcomes

NRF2–KEAP1 antioxidant response

upin worms1

1 study

Lupiwighteone activates NRF2–KEAP1 antioxidant response in worms.
“Lup activated the MAPKs/Nrf2 pathway, enhanced antioxidant stress responses, and reduced oxidative damage”
Model organisms
Lupiwighteone exerts anti-aging effects by suppressing NF-κB and activating the MAPKs/Nrf2 signaling pathway
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP26 Jan 2026

More on NRF2–KEAP1 antioxidant response

Reactive oxygen species

downin worms1

1 study

Lupiwighteone decreases reactive oxygen species in worms.
“reduced reactive oxygen species (ROS) levels”
Model organismsLup treatment
Lupiwighteone exerts anti-aging effects by suppressing NF-κB and activating the MAPKs/Nrf2 signaling pathway
Comparative biochemistry and physiology. Toxicology & pharmacology : CBP26 Jan 2026

Latest

1 in 12 months

Comparative Biochemistry and Physiology Toxicology & Pharmacology29 Jan

Lupiwighteone exerts anti-aging effects by suppressing NF-κB and activating the MAPKs/Nrf2 signaling pathway

Experiments in wormsInterventions

Paper

Lupiwighteone

Outcomes

Latest

Lupiwighteone exerts anti-aging effects by suppressing NF-κB and activating the MAPKs/Nrf2 signaling pathway

Related